Skip to main content
# Title Department Research Year
61 Design, synthesis, and apoptotic antiproliferative action of new 1,2,3-triazole/1,2,4-oxadiazole hybrids as dual EGFR/VEGFR-2 inhibitors. Department of Pharmaceutical Organic Chemistry 2024
62 Selective and reliable fluorometric quantitation of anti-cancer drug in real plasma samples using nitrogen-doped carbon dots after MMIPs solid phase microextraction: Monitoring methotrexate plasma level Department of Pharmaceutical Analytical Chemistry 2024
63 Design and synthesis of novel quinoline-ester/-amide derivatives as potent antiproliferative agent targeting EGFR and BRAFV600E kinases Department of Pharmaceutical Organic Chemistry 2024
64 Regiodivergent biosynthesis of bridged bicyclononanes Department of Pharmacognosy 2024
65 Development of Oral Formulation of Lepidium Seeds Significantly Decreases the High Blood Glucose Levels in Diabetic Rats; In Vitro Formulation and In Vivo Antidiabetic Performance. Department of Industrial Pharmacy 2024
66 Pharmaceutical interventions for drug-related problems in the neonatal intensive care unit incidence, types, and acceptability Department of Clinical Pharmacy 2024
67 Enhanced fluorescent detection of oxaliplatin via BSA@ copper nanoclusters: a targeted approach for cancer drug monitoring Department of Pharmaceutical Analytical Chemistry 2024
68 Zirconium-based hydrophobic-MOFs as innovative electrode modifiers for flibanserin determination: Exploring the electrooxidation mechanism using a comprehensive spectroelectrochemical study Department of Pharmaceutical Analytical Chemistry 2024
69 Design, synthesis, and biological evaluation of novel quinoline-based EGFR/HER-2 dual-target inhibitors as potential antitumor agents Department of Pharmaceutical Organic Chemistry 2024
70 MCT4 knockdown by tumor microenvironment-responsive nanoparticles remodels the cytokine profile and eradicates aggressive breast cancer cells Department of Industrial Pharmacy 2024